|
|
|
|
||
Re: patient updates"Mabel has now conceded that the treatment worked for ALL patients but was not durable in half of them. This means that a re-dose that again raises the T-cell count against HPV6/11 would likely work again in these patient and some may actually be pushed into remission. After the first surgery, the data show few patients having faster RRP growth going forward but an equal number having slower growth." once again the clueless idiot is not able to comprehend what people write about as I have not conceded anything because your belief is based on a falsehood. Again, what I have said about prgn-2012 after the data was released is that the treatment shows durability on the remission patients because the virus as been cleared but on the non-remission patients the treatment only works up to a certain point in time before the virus reasserts itself. This lack of durable response is the reason I stated that the data on the non-remission patients was mixed for me and that these patients are going to require additional dosing to either clear the virus or go on maintenance program by getting an injection possibly every 2-3 months. Precigen needs to understand what the reason why some patients go into remission while others do not when clinically none of these patients are different. I have also stated that Precigen needs to initiate a redosing study as soon as possible to see if additional injections might solve this durability problem. A severe rrp patient will gladly take 4-6 shots per year of 2012 for the rest of their lives if it eliminates the need for surgery other than maybe once a year. Let's take patient #9 as an example. She went approx 160 days before requiring surgery but papilloma were growing well before her surgery. So what would have happened if on her 12 week check up she would have had another injection and than another injection every 3 months. Would that dosing frequency while not maybe clearing her HPV at least kept at bay any papilloma growth. The reason I said I put much more weight on the percentage of remission patients is because this current 2012 trial will not be approved based upon the partial and non-responders as there is a durability issue which needs to be resolved. If Precigen can identify in advance of treatment which patients will go into remission and which will not, it will be highly material on multiple fronts. For me, durability has always been a concern as can be seen from a post of mine below after Dr Allen presented initial incomplete data on the first 3/7 patients. quick commentprgn-2012 was very positive but we only have a glimpse on 3 patients and it is too short of a time frame to see the durability of the treatment. But it is a really encouraging start. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
52820 | Re: patient updates | Redwood1205 | 0 | 2/4/2023 11:55:30 AM |